Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sk Biopharmaceuticals Co., Ltd. (326030:KRX), powered by AI.
Sk Biopharmaceuticals Co., Ltd. is currently trading at ₩90,200. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sk Biopharmaceuticals Co., Ltd. on Alpha Lenz.
Sk Biopharmaceuticals Co., Ltd.'s P/E ratio is 26.5.
“Sk Biopharmaceuticals Co., Ltd. trades at a P/E of 26.5 (premium valuation) with strong ROE of 39.3%. 3Y revenue CAGR of 42.1% highlights clear growth momentum.”
Ask for details →Sk Biopharmaceuticals Co., Ltd. is a leading biomedical company primarily engaged in the research, development, and commercialization of innovative pharmaceutical products. This company operates with a strong focus on central nervous system (CNS) disorders, aiming to address unmet medical needs through its proprietary drug development programs. One of its notable achievements includes the development of therapies for epilepsy and Parkinson's disease, which highlights its commitment to advancing treatments in the CNS sector. Additionally, Sk Biopharmaceuticals is actively expanding its portfolio through strategic partnerships and collaborations in the biopharmaceutical industry. By leveraging advanced research facilities and a robust pipeline of clinical stage assets, the company plays a significant role in contributing to the pharmaceutical market's landscape. Its presence is crucial in enhancing the availability of targeted therapies, ultimately improving patient outcomes across global healthcare systems.
“Sk Biopharmaceuticals Co., Ltd. trades at a P/E of 26.5 (premium valuation) with strong ROE of 39.3%. 3Y revenue CAGR of 42.1% highlights clear growth momentum.”
Ask for details →Sk Biopharmaceuticals Co., Ltd. (ticker: 326030) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 246 employees. Market cap is $7.1T.
The current price is ₩90,200 with a P/E ratio of 26.46x and P/B of 8.69x.
ROE is 39.28% and operating margin is 28.86%. Annual revenue is $706.7B.